Sunwin International Neutraceuticals Inc. (OTC BB: SUWN $0.16) November 06, 2005 Greetings!
In only 10 short years, China will be a powerhouse, one of the top economies in the world. Now a member of the World Trade Organization, China has thrown open the gates to foreign investment. Billions have already flooded in. The smart money knows: fortunes are being made.
Trading at 8 times fiscal ’05 earnings, Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN $0.16) poses a tremendous opportunity for U.S. investors to participate in the growth of the Chinese economy. One of 2,000 state-level companies authorized as the most important innovative high- tech pioneer businesses by the Chinese Central Government, SUWN targets their line of neutraceutical products at 3 separate markets.
SUWN’s Three Divisions $5.5 million of SUWN's fiscal ’05 revenue came from Stevioside, a 100% natural sweetener extracted from the leaves of the Stevia rebaudiana plant. One of China’s leading manufacturers of Stevioside, SUWN sells this product on a wholesale basis to domestic food manufacturers and larger foreign trade companies which export the product to Japan, Korea and Southeast Asia. In 2002, China accounted for 1,200 tons of the global supply of Stevioside. SUWN was responsible for 16% of global production. $3.3 million of SUWN's fiscal ‘05 revenue came from their veterinary medicine division. Traditional Chinese and Western medicine, feed additives, feeds and disinfectors are sold domestically on both a wholesale and retail basis to livestock and poultry farmers, retail veterinary product outlets and large scale cultivating business. SUNW is one of the top 50 companies in this product category in China. In March, 2005, SUWN's scientists announced the development of a new series of veterinary disinfectants against the Bird Flu Virus based on Chinese herbal technology that Sunwin owns. In addition to killing any kind of Bird Flu Virus, it meets national sanitary standards and does not cause pollution to the environment.
$3 million of fiscal ‘05 revenues came from traditional Chinese medicine formula extracts, sold on a wholesale basis to domestic traditional Chinese medicine manufacturers and large animal pharmaceutical companies.
U.S. Investors Profit From Chinese Companies Investors in Netease.com (NTES), with an average annual return of 283% between 2001 and 2004 and China Yuchai International (CYD), with an average annual return of 158% in the same years, have made millions. Sinovac Biotech (SVA) had an increase in share price from $0.50 to over $6.00 in two years, an amazing 1,200% in just over 24 months. Investors who put up $10,000 in 2003 have seen their money grow to $120,000 in 2005.
Research & Development To keep its products scientifically advanced and develop new products, SUWN has formed a R&D relationship with the China Science Bureau, Shandong Biological Science Institute, China Medical University, Beijing Medical University, Shandong Medical University and Shandong Agriculture University. One year ago, SUWN invested US $360,000.00 to set up a research fund for science and technology development at the Shandong University of Traditional Chinese Medicine for the development of new medicines that have potential commercial applications. The research projects will comprise new medicine screening, laboratory research, animal test and clinical trial for fast tracking the final clearance from the government agency for sale. The key is to focus on new innovations of medicines that have yet to complete the required clinical reporting, as well as the creation of a host of new applications of Chinese traditional medicine.
Summary and Valuation The average P/E in the Wholesale Drug Industry is 22.8. Using SUWN’s $0.02 a share in earnings for fiscal ’05 should put the stock in the $0.45 area. We can also apply a discount to SUWN since its operations are in China and the stock is fairly low priced. Even with such a discount we could easily see a double from here. Take in to consideration the rapid growth in the Chinese economy and the potential could be much greater. Investment returns like those we’ve already mentioned could be just the beginning. There has never been an opportunity like this in history. If you are ready to participate in the fortunes being made as China charges to the lead in the Global Economic Race, then you may not need to look any further than Sunwin International Neutraceuticals, Inc. (SUWN).
OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. The information in this newsletter is not an offer to buy or sell securities of the companies profiled. Information is for informative purposes, not intended as investment advice, and is subject to change without notice. OTC Stock Review has been compensated $10,000.00 to perform investor relations services for Sunwin International Neutraceuticals Inc. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled company and may from time to time trade in these securities for their own accounts. Information on each company is from public releases and can not be guaranteed by OTC Stock Review. Companies profiled herein may carry a high investment risk; readers should carefully review the profiled companies thoroughly with their investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled Companies. Reader’s are encouraged to obtain copies of the profiled Company’s periodic reports filed with United States Securities and Exchange Commission which are generally available at http://www.sec.gov.
Sunwin International Neutraceuticals, Inc.: SUWN Announces 100% Increased Sales of Hypericin Related Products Against Bird Flu Virus via COMTEX
April 5, 2006
Apr 05, 2006 (M2 PRESSWIRE via COMTEX News Network) --
Fort Lauderdale, FL and Qufu, China - Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN), an industry leader in the production and distribution of Chinese herbs, veterinary medicines and low calorie natural sweetener in China, announced continued increases in sales of Hypericin based products. In November 2005, Sunwin launched a marketing effort for two products employing Hypericin as a main component to deter the spread of the avian flu. Since the launch of the marketing efforts, the combined sales of both products increased from 342,300 RMB per month in November 2005 to 685,800 RMB per month in February 2006.
Hypericin is a derivative of St. Johns Wort, which is an English word for a Chinese herb manufactured by Sunwin since 1997. In recent laboratory tests, Hypericin has proven effective as a treatment for poultry infected with strands of the avian flu. The in vitro experiments, performed jointly by the South China Agricultural University and the Chinese Academy of Agricultural Sciences, indicated that when H5N1 and H9N2 avian flu viruses were treated with Hypericin at 3.72 mg/ml for 30 minutes, Hypericin was treating 100% of the viruses. Furthermore, when these viruses were treated with Hypericin at 0.744 mg/ml for 10 minutes, Hypericin was successful in treating over 99.99% of the viruses.
Sunwin coordinated on a joint project with scientists from the e Traditional Chinese Medicine department of Shangdong University, the results were two products which could suppress the spread of certain strands of the avian flu. The two products are marketed to the veterinary community in China as a food additive. The products are mixed with water to feed poultry as a preventative measure to assist in the efforts to prevent the spread of the avian flu.
In November, 2005 Sunwin announced the Department of Livestock Farming for Shandong Province Government submitted a fast-track application to the Livestock Farming Bureau of China Ministry of Agriculture for approval of Hypericin related products as a class one new veterinary medicine to treat strands of the avian flu virus. While the China Ministry of Agriculture has not provided such clearance as a class one application Sunwin can distribute as a veterinary feed additive within China.
Laiwang Zhang, President and Chairman of Sunwin International Neutraceuticals, Inc., stated, "As we await ruling on Hypericin as a class one veterinary medical application, we launched our two products for sale as a regular veterinary feed additive. The preliminary response has been favorable, and we continue to witness steady growth in sales of these two products. "
About Sunwin International Neutraceuticals, Inc.
Sunwin International Neutraceuticals, Inc. (OTCBB: SUWN) is engaged in the areas of essential traditional Chinese medicine, 100% organic herbal medicine, neutraceutical products, low-calorie natural sweetener (Stevia), and veterinary medicines and feeds prepared from 100% organic herbal ingredients. As an industry leader in agricultural processing, Sunwin has built an integrated global firm with the sourcing and production capabilities to meet the needs of consumers throughout the world. Sunwin also makes such value-added products as specialty veterinary food ingredients and specialty feed ingredients. The Sunwin family works closely with consumer to provide a quality and a hybrid mix of agricultural products and services that meet growing demand. In 2002, Sunwin was recognized as one of the first 2,000 state-level companies that China authorized as the most important innovative high-tech pioneer businesses by the Chinese central government. In 2002, Sunwin was awarded as one of 2002 state-level biological product manufacturers in China. In 2003, Sunwin ranked as one of the top 50 companies of China Animal Related Health Care Product Pharmaceutical Industry. In 2003, Sunwin received award of Shandong Top-Ten Innovative, High-Tech Businesses by the Province Government of Shandong. For more info about Sunwin, please visit http://www.sunwin.biz Safe Harbor Statement Certain of the statements set forth in this press release constitute "forward-looking statements." Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intend," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may" or words or expressions of similar meaning. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited financial resources, domestic or global economic conditions -- especially those relating to China, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws, restrictions and regulations on doing business in a foreign country, in particular China, and conditions of equity markets. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.
CONTACT: Jimmy Glickstein Tel: +1 877 China 57 e-mail: info@sunwin.biz
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com. (C)1994-2006 M2 COMMUNICATIONS LTD
Disclaimer-my stocks are per the advice of my lucky eight ball, please seek your own professional consultant ............................................
If at first you don't succeed, then skydiving definitely isn't for you
Logged
